Howard Colman

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial

  Journal of Clinical Oncology · 2026-04-14 · 1 citations

• Comprehensive analysis of TEAD inhibition in meningioma identifies MEK and mTOR inhibition as effective combination therapies against resistant lines

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-03-24

• Stereotactic radiosurgery for radiation‑induced meningiomas: long‑term institutional outcomes with patient- and lesion‑level analyses and an updated meta‑analysis

  Journal of Neuro-Oncology · 2025-12-15

• STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma

  Journal of Clinical Oncology · 2025-12-01 · 1 citations

• Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors

  Nature Communications · 2025-11-13 · 4 citations

• PATH-82. Multivariate survival risk stratification in GBMs lacking necrosis and microvascular proliferation

  Neuro-Oncology · 2025-11-01

• CTP-18. PNOC025: A phase 1 study assessing the safety and tolerability of magrolimab in children and adults with recurrent or progressive malignant brain tumors

  Neuro-Oncology · 2025-11-01

• CTNI-58. UPDATED RESULTS OF PHASE 3 STELLAR TRIAL: EFLORNITHINE IMPROVES OVERALL SURVIVAL AND BLINDED INDEPENDENT CENTRAL REVIEW DETERMINED PROGRESSION FREE SURVIVAL IN PATIENTS WITH RECURRENT WHO 2021 GRADE 3 IDH-MUTANT ASTROCYTOMA

  Neuro-Oncology · 2025-11-01

• QLTI-08. Single institution experience with romiplostim for chemotherapy-induced thrombocytopenia in gliomas

  Neuro-Oncology · 2025-11-01

• EXTH-131. Combined Inhibition of RAF, MEK, and FAK Attenuates Brain Metastases and Prolongs Survival in Melanoma Preclinical Models

  Neuro-Oncology · 2025-11-01

• Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma

  Current Oncology · 2025-09-27 · 2 citations

• Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

  UNC Libraries · 2025-07-31

• Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

  UNC Libraries · 2025-07-31

• Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

  Nature Medicine · 2025-07-21 · 1 citations

• Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.

  Journal of Clinical Oncology · 2025-05-28 · 1 citations

• Combined inhibition of focal adhesion kinase and RAF/MEK elicits synergistic inhibition of melanoma growth and reduces metastases

  Cell Reports Medicine · 2025-02-01 · 12 citations

• Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy

  Cells · 2024-12-03 · 3 citations

• CTNI-48. A PHASE 1 STUDY OF ERAS-801, A POTENT, SELECTIVE, AND CENTRAL NERVOUS SYSTEM (CNS)-PENETRANT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR, FOR PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM)

  Neuro-Oncology · 2024-11-01 · 4 citations

• LTBK-01. PHASE 3 STELLAR STUDY SHOWS EFLORNITHINE IMPROVES OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH RECURRENT 2021 WHO ASTROCYTOMA, IDH-MUTANT GRADE 3

  Neuro-Oncology · 2024-11-01 · 2 citations

• LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

  Neuro-Oncology · 2024-11-01 · 2 citations